ClinicalTrials.gg
RecruitingNCT07028008Updated Nov 19, 2026

Evaluate the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocyte in Patients With Refractory Melanoma Who Failed to Immune Checkpoint Inhibitors

An interventional study of tumor-infiltrating lymphocyte (TIL) in Melanoma, sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 19, 2026Now RecruitingFirst site in South Korea+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies testing Therapeutic Tumor Infiltrating Lymphocytes in Melanoma — 3 open to participants now, 4 under way, none of them phase 3. Therapeutic Tumor Infiltrating Lymphocytes · Melanoma.

Planned enrollment
11th of 15
9 · median 12
Started
2025
with 1 other
No phase
Only one
of the 15
Registered
14th of 15
by date
Lead sponsor
1 of 15
Samsung Medical Center

Among the 15 studies testing Therapeutic Tumor Infiltrating Lymphocytes in Melanoma, this one is the 11th largest by planned enrollment, is one of 2 that started in 2025, is the only one with no phase, and was the 14th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 15 studies testing Therapeutic Tumor Infiltrating Lymphocytes in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Therapeutic Tumor Infiltrating Lymphocytes

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing Therapeutic Tumor Infiltrating Lymphocytes in Melanoma, or all of them as a file.
02

Study summary

For cancer patients who have failed conventional chemotherapy or are inoperable, targeted therapies-which block specific proteins involved in tumor growth-and immunotherapies-which activate T cells around the tumor to induce tumor cell death-have emerged as powerful treatment options. These therapies often result in longer survival with fewer side effects compared to traditional chemotherapy. However, a significant proportion of patients do not respond to either targeted therapies or immunotherapies, and treatment options for these individuals remain extremely limited.

One of the most notable immunotherapies, immune checkpoint inhibitors, works by blocking immune checkpoint proteins (such as PD-1 and CTLA-4) to activate T cells within the tumor microenvironment, thereby enabling them to attack cancer cells. This approach has demonstrated remarkable efficacy in various solid tumors, including melanoma. Nonetheless, for many patients with immunologically "cold" tumors characterized by low infiltration of T cells, these therapies show low objective response rates, indicating the need for more proactive treatment strategies.

In this study, we aim to administer the tumor-infiltrating lymphocyte (TIL) therapy CT-SP to patients with refractory melanoma, primarily to assess safety, and further to evaluate its anti-tumor efficacy by examining improvements in objective response rate (ORR) and progression-free survival (PFS). If this advanced regenerative clinical study demonstrates that CT-SP is both safe and effective, it could offer a powerful new treatment option for patients with refractory melanoma in Korea.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • melanoma
  • TIL
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥19 and ≤80 years at the time of .
  2. or cytologically confirmed melanoma, classified as /unresponsive Stage IIIc or IV after failure of prior therapy.
  3. At least one measurable and evaluable lesion as defined by version 1.1.
  4. performance status of 0 or 1.
  5. Estimated ≥12 weeks.
  6. Ability to undergo tumor tissue for the purpose of producing a sufficient quantity of autologous tumor-infiltrating lymphocytes (CT-SP).

    • Willingness to undergo tissue collection procedures after enrollment in the study.
    • For surgical specimens: at least one lesion with a minimum diameter of 1 cm. For biopsy samples: a minimum of 20-25 tissue fragments must be obtainable.
  7. Adequate organ function as defined by the following laboratory values (up to two retests permitted; transfusions or medical correction allowed):

    • ≥ 9.0 g/dL
    • (ANC) ≥ 1,500/μL
    • Absolute Lymphocyte Count (ALC) ≥ 500/μL
    • count ≥ 100,000/μL
    • Serum (estimated by Cockcroft-Gault) ≥ 50 mL/min
    • Total ≤ 2.0 mg/dL
    • and/or ALT ≤ 3 × (≤ 5 × ULN if liver is present)
  8. Subjects of must agree to use acceptable methods during the study, including but not limited to:

    Complete abstinence, Sterilization (patient or partner), Intrauterine device, Hormonal contraception, Barrier methods (e.g., condom + spermicide, diaphragm)

  9. Written informed consent voluntarily provided before any study-specific procedures are conducted.

Exclusion criteria

Exclusion Criteria:

  1. History of solid organ transplantation.
  2. Diagnosis of another within the past 5 years, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or non-invasive cervical cancer.
  3. History of active or latent tuberculosis infection within 1 year prior to screening (except for those declared cured after treatment).
  4. Pregnant or breastfeeding women.
  5. Positive test for anti- antibodies.
  6. Active or infection considered clinically inappropriate for study participation by the investigator.
  7. Uncontrolled central nervous system (CNS) (note: patients with treated and stable for ≥30 days prior to screening are eligible).
  8. Any surgery, radiotherapy, or systemic anticancer therapy within 3 weeks prior to CT-SP administration.
  9. Participation in another interventional clinical trial and receipt of any drug within 3 weeks prior to CT-SP administration.
  10. Known or to: Cyclophosphamide, Fludarabine, Interleukin-2 (IL-2), CT-SP : 5% human serum albumin, sterile saline, 5% DMSO
  11. Unresolved toxicity from prior therapy not recovered to Grade ≤1 (per v5.0), except for clinically non-significant events such as alopecia.
  12. Receipt of systemic therapy (including ) within 10 days prior to tumor tissue collection for CT-SP manufacturing (exceptions: local/inhaled steroids; systemic corticosteroids ≤ prednisolone 20 mg/day equivalent may be permitted at investigator discretion).
  13. cardiovascular disease, including but not limited to:

    Uncontrolled hypertension (systolic BP > 180 mmHg and/or diastolic BP > 100 mmHg), Unstable angina, Pulmonary embolism, Cerebrovascular accident, Valvular heart disease, Congestive heart failure ( Class III or IV), Myocardial infarction or significant arrhythmia within 24 weeks prior to screening

  14. Known contraindications to dopamine or other pressor agents.
  15. Other serious comorbid medical conditions that may interfere with study participation, as determined by the investigator.
  16. Active or severe infection requiring hospitalization or intravenous antibiotics, deemed unsuitable for participation by the investigator.
  17. Significant psychiatric illness that, in the investigator's opinion, may affect subject compliance or study conduct.
  18. Subjects with or inflammatory disorders, where the investigator deems abnormal autoantibody test results to be clinically relevant.
  19. Any other condition not listed above that the investigator considers to make the subject ineligible for participation.
  20. Subjects determined to be unsuitable for participation based on the anticipated manufacturing timeline and logistics of CT-SP.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    tumor-infiltrating lymphocyte (TIL) therapy

    1\~100 x 10 9 cells, 1time, IV

    Biological: tumor-infiltrating lymphocyte (TIL)

Interventions

06

What researchers measure

Primary outcomes

  1. Safety evaluation

    Incidence of tumor infiltration lymphocyte (CT-SP) treatment Adverse Events as assessed by CTCAE v5.0

    Time frame: up to 6 months after TIL administration

Secondary outcomes

  1. Overall Response Rate

    modified Recist v1.1

    Time frame: Up to 60months

  2. Duration of Response

    modified Recist v1.1

    Time frame: Up to 60months

  3. Disease Control Rate

    modified Recist v1.1

    Time frame: Up to 60months

  4. Progression Free Survival

    modified Recist v1.1

    Time frame: Up to 60months

  5. Overall Survival

    modified Recist v1.1

    Time frame: Up to 60months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.

Of 220 non-industry interventional studies with no phase under Melanoma, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 22 months is below that.

Counting every sponsor, half of 228 studies reached it within 38 months; a quarter within 20 and three quarters within 62.

Start moved once since we started tracking on Sep 25, 2026: Oct 2025 → Jul 2025, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jun 19, 2025
StartActual
Jul 2, 2025was Oct 2025
Primary completionEst.
May 28, 2027
CompletionEst.
May 28, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
1 site added — first site in South Korea
Show site
  • Samsung Medical Center · Seoul, South Korea
Nov 19, 2026
Start date
Oct 15, 2025→Jul 2, 2025 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in South Korea
    Show site
    • Samsung Medical Center · Seoul, South Korea
    Start date Oct 15, 2025→Jul 2, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07028008
Responsible party
Jeeyun Lee (Principal Investigator, Samsung Medical Center) — Principal investigator
First posted
Jun 19, 2025
Start date
Jul 2, 2025
Primary completion
May 28, 2027 (estimated)
Completion
May 28, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Jeeyun Lee Principal Investigator, MD
Contact
jyun.lee@samsung.com
82-2-3410-3459

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Therapeutic Tumor Infiltrating Lymphocytes

Start the discussion